ImmuneXcite Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

ImmuneXcite General Information

Description

Developer of next generation immune-activating anti-tumor biotherapeutics designed to leverage both the innate and adaptive immune responses to selectively treat a wide range of tumor type. The company's immune-activating anti-tumor biotherapeutics use novel immunotherapy platform that is focused on developing monoclonal antibodies which identifies a fungal carbohydrate responsible for stimulating the innate immune system, enabling health care providers to limit tumor growth and metastasis in patient's body.

Contact Information

Website
www.immunexcite.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 266 2nd Avenue
  • Suite C
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 266 2nd Avenue
  • Suite C
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuneXcite Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 12-Oct-2017 Completed Out of Business
6. Early Stage VC 01-Feb-2017 Completed Generating Revenue
5. Later Stage VC (Series A1) 30-Mar-2016 Completed Generating Revenue
4. Later Stage VC (Series B) 20-Dec-2013 Completed Generating Revenue
3. Grant 04-Sep-2013 Completed Generating Revenue
2. Debt - General 19-Dec-2012 $984K $3.4M Completed Startup
1. Seed Round 03-Jan-2012 $2.42M $2.42M Completed Startup
To view ImmuneXcite’s complete valuation and funding history, request access »

ImmuneXcite Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A1
To view ImmuneXcite’s complete cap table history, request access »

ImmuneXcite Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of next generation immune-activating anti-tumor biotherapeutics designed to leverage both the innate and adapt
Biotechnology
Waltham, MA

Andover, MA
 

Barcelona, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmuneXcite Competitors (88)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oncorus Formerly VC-backed Andover, MA
Ability Pharma Private Equity-Backed Barcelona, Spain
Adimab Venture Capital-Backed Lebanon, NH
NexImmune Formerly VC-backed Gaithersburg, MD
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
You’re viewing 5 of 88 competitors. Get the full list »

ImmuneXcite Patents

  • 36

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

ImmuneXcite Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3551685-A1 ß-1,6-glucan trastuzumab antibody conjugates Inactive 07-Dec-2016
EP-3582810-A1 ß-1,6-glucan therapeutic antibody conjugates Pending 07-Dec-2016
EP-3582810-A4 ß-1,6-glucan therapeutic antibody conjugates Pending 07-Dec-2016
US-20200030360-A1 ß-1,6-glucan therapeutic antibody conjugates Active 07-Dec-2016
US-11865135-B2 ß-1,6-glucan therapeutic antibody conjugates Active 07-Dec-2016 A61K31/716
To view ImmuneXcite’s complete patent history, request access »

ImmuneXcite Executive Team (12)

Name Title Board Seat
Gerald Fink Ph.D Co-Founder & Advisor
Eric Furfine Ph.D Chief Scientific Officer, Board Member and Acting Chief Executive Officer
Drew Pardoll Ph.D Scientific Advisory Board Member
You’re viewing 3 of 12 executive team members. Get the full list »

ImmuneXcite Board Members (7)

Name Representing Role Since
Eric Furfine Ph.D Self Chief Scientific Officer, Board Member and Acting Chief Executive Officer
Eric Rowinsky MD Self Board Member
James Geraghty JD Self Board Member
Valerie Friedman Self Board Member
You’re viewing 4 of 7 board members. Get the full list »

Ready to get started?

Request a free trial

ImmuneXcite FAQs

  • When was ImmuneXcite founded?

    ImmuneXcite was founded in 2007.

  • Who is the founder of ImmuneXcite?

    Ifat Rubin-Bejerano Ph.D, Gerald Fink Ph.D, and Yaniv Bejerano are the founders of ImmuneXcite.

  • Where is ImmuneXcite headquartered?

    ImmuneXcite is headquartered in Waltham, MA.

  • What industry is ImmuneXcite in?

    ImmuneXcite’s primary industry is Biotechnology.

  • Is ImmuneXcite a private or public company?

    ImmuneXcite is a Private company.

  • What is ImmuneXcite’s current revenue?

    The current revenue for ImmuneXcite is .

  • How much funding has ImmuneXcite raised over time?

    ImmuneXcite has raised $20.3M.

  • Who are ImmuneXcite’s competitors?

    Oncorus, Ability Pharma, Adimab, NexImmune, and Aro Biotherapeutics are some of the 88 competitors of ImmuneXcite.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »